CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
Hyuk Yoon
Intest Res. 2019;17(3):283-284.   Published online July 25, 2019
DOI: https://doi.org/10.5217/ir.2019.00070

Excel Download

Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
Intestinal Research. 2019;17(3):283-284   Crossref logo
Link1 Link2 Link3

Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
Gastroenterology. 2014;146(1):e14-e15   Crossref logo
Link1 Link2

Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients
Pediatric Health, Medicine and Therapeutics. 2012;51   Crossref logo
Link1

Severe ulcerative colitis
Current Treatment Options in Gastroenterology. 1999;2(2):113-118   Crossref logo
Link1 Link2 Link3

Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab
Crohn's Disease and Ulcerative Colitis. 2017;429-433   Crossref logo
Link1

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
Therapeutics and Clinical Risk Management. 2013;451   Crossref logo
Link1

Su1827 - Markers of Systemic Inflammation in Moderate-Severe Ulcerative Colitis: What Level of C-Reactive Protein Constitutes Acute Severe Ulcerative Colitis?
Gastroenterology. 2018;154(6):S-598   Crossref logo
Link1 Link2

Cost-Utility Analysis of Adalimumab for The Treatment of Moderate-To-Severe Ulcerative Colitis In Patients In Spain
Value in Health. 2015;18(7):A670   Crossref logo
Link1 Link2

Mo1325 Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis
Gastroenterology. 2013;144(5):S-637   Crossref logo
Link1 Link2

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis
Journal of Crohn's and Colitis. 2014;8(7):571-581   Crossref logo
Link1 Link2 Link3